Quilizumab
As of the edition of 20 October 2026, Quilizumab is an antibody: went quiet in 2014; acts on IGHE.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2014
- Kind
- Antibody
- Registered trials
- 3, 0 stopped early
- Disease areas
- Immune system; Lungs and airways; Ear, nose and throat
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| IGHE | Immunoglobulin heavy constant epsilon | P01854 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 2 | 2 | 0 | 0 |
| All trials | 3 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Roche | Lead sponsor of trials | 2010 to now |